Temodar® (temozolomide) – Updated indication
September 14, 2023 - The FDA announced the approval of Merck’s Temodar (temozolomide), for the adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma and treatment of adults with refractory anaplastic astrocytoma.
Download PDF
